Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion

NCT01889186 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01889186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01889186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
June 27, 2013
Completion date
December 15, 2020
Enrollment
158 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

17p deletion, cancer of the blood and bone marrow, chronic lymphocytic leukemia